Dismay over the price of prescription drugs continues to pervade politics and popular culture. Last year, the Inflation Reduction Act, with its Medicare Part D redesign and drug negotiation provisions, shifted the dynamics of the prescription drug market and policymakers continue to look for ways to address high drug costs. Proposed solutions include boosting competition by reducing paten abuses, increasing the number of biosimilars on the market, and exploring the role of pharmacy benefit companies (PBMs).
PCMA’s Policy Forum featured policymakers – including key Administration officials and Congressional staffers – and PBM executives to discuss how the public and private sectors are tackling drug costs and improving both the affordability and quality of care for patients. Speakers addressed topics highlighted in the PCMA Affordable Future policy platform, which focuses on increasing competition to bolster the private market, providing clinicians with data and tools to enhance patient care, and supporting and protecting patients.
Video Highlights
Welcome
JC Scott, President & Chief Executive Officer, PCMA
Ian Spatz, National Advisor, Manatt, Phelps & Phillips
Competition and Client Choices in the PBM Marketplace
James Gartner, President, PerformRx
IRA Update: Implementation and Public Engagement
Meena Seshamani, MD, PhD, Deputy Administrator and Director, Center for Medicare
How PBMs are Addressing Rising Healthcare Costs
William Fleming, President, Pharmacy Solutions and Chief Corporate Affairs Officer, Humana
How PBMs Support Providers and Patients and the Point of Prescribing
Lisa Smith, Chief of Operations, Optum Rx
Using Evidence to Achieve Prescription Drug Access and Affordability
Sarah K. Emond, MPP, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER)
Beyond Price Negotiations: How PBM Clinical Programs Work to Optimize Patient Outcomes
Christine Gilroy, Chief Medical Officer, Express Scripts
Reactions and Thoughts on Current Proposals to Lower Drug Costs and Improve Competition
Scott Gottlieb, M.D., Former United States Commissioner, U.S. Food & Drug Administration
PCMA Policy Forum 2023 Agenda
| 11:15 am - 3:45 pm | Registration Open
| |
| 11:15 am - 12:00 pm | Networking Lunch | |
| 12:00 pm - 12:15 pm | Welcome JC Scott, President & Chief Executive Officer, PCMA Ian Spatz, National Advisor, Manatt, Phelps & Phillips | |
| 12:15 pm - 12:45 pm | Capitol Hill Perspectives on Proposals to Address Drug Costs – Closed to Media Katie McInnis, Chief Counsel, House Subcommittee on Administrative State, Regulatory Reform, and Antitrust Franci Rooney, Counsel, Senator John Cornyn, Senate Judiciary Committee | |
| 12:45 pm - 1:10 pm | Competition and Client Choices in the PBM Marketplace James Gartner, President, PerformRx | |
| 1:10 pm - 1:35 pm | IRA Update: Implementation and Public Engagement Meena Seshamani, MD, PhD, Deputy Administrator and Director, Center for Medicare | |
| 1:35 pm - 2:00 pm | How PBMs are Addressing Rising Healthcare Costs William Fleming, President, Pharmacy Solutions and Chief Corporate Affairs Officer, Humana | |
| 2:00 pm - 2:25 pm | How PBMs Support Providers and Patients and the Point of Prescribing Lisa Smith, Chief of Operations, Optum Rx | |
| 2:25 pm - 2:50 pm | Using Evidence to Achieve Prescription Drug Access and Affordability Sarah K. Emond, MPP, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER) | |
| 2:50 pm - 3:15 pm | Beyond Price Negotiations: How PBM Clinical Programs Work to Optimize Patient Outcomes Christine Gilroy, Chief Medical Officer, Express Scripts | |
| 3:15 pm - 3:45 pm | Reactions and Thoughts on Current Proposals to Lower Drug Costs and Improve Competition Scott Gottlieb, M.D., Former United States Commissioner, U.S. Food & Drug Administration |
